胰腺癌患者血清可溶性CD44及CD44变异体6临床研究

Clinical study of level of serum soluble CD44 and CD44 variant 6 in pancreatic carcinoma

目的 :观察胰腺癌患者的血清可溶性 CD44标准体 ( s CD44 s)及可溶性 CD44变异体断片 6( s CD44 v6)水平及其临床意义。方法 :采用酶联免疫吸附法检测 93例胰腺癌 ,3 0例正常人血清 s CD44 s和 s CD44 v6含量 ,并分析其与临床病理之间的关系。结果 :胰腺癌患者中血清 s CD44 s和 s CD44 v6明显减少 ( n=93 ,P<0 .0 0 1和 P<0 .0 0 0 5 ,s CD44 v6与临床病理之间有相关性。结论 :s CD44 v6与胰腺癌临床病理分期有关 ,检测血清 s CD44

Objective:To observe the level soluble forms of CD44 standard(sCD44 s) and CD44 variant 6(sCDv6) in patient with pancreatic carcinoma and study its clinical significance.Methods:Serum sCD44 s and sCD44v6 were measured with enzyme-linked immunosorbent assay(ELISA) in 93 patients with pancreatic carcinoma and 30 healthy subject,compared with clinical pathologic.Results:The level of serum sCD44v6 and sCD44 s were significantly reduced in patients with pancreatic carcinoma(n=93, P <0.001 and P <0.0005),and correlated with clinical data.Conclusions:The results suggest that sCD44v6 is related to clinical pathologic stage;the detection of sCD44v6 is useful in assessment of the disease status and the prognosis of the pancreatic carcinoma.